120 related articles for article (PubMed ID: 8586759)
1. Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture.
Muto M; Furumoto H; Ohmura A; Asagami C
J Dermatol; 1995 Oct; 22(10):770-2. PubMed ID: 8586759
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of ACTH and alpha-MSH in vitiligo patients successfully treated with a sex steroid-thyroid hormone mixture.
Ichimiya M
J Dermatol; 1999 Aug; 26(8):502-6. PubMed ID: 10487004
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of non-segmental vitiligo: systemic therapy with sex hormone-thyroid powder mixture.
Nagai K; Ichimiya M; Yokoyama K; Hamamoto Y; Muto M
Horm Res; 2000; 54(5-6):316-7. PubMed ID: 11595825
[TBL] [Abstract][Full Text] [Related]
4. [Metharmon F for glossalgia caused by autonomic dysfunction].
Densho S; Ohama G; Yamamoto E; Komatsu Y; Genba R
Shikai Tenbo; 1985 Aug; 66(2):455-60. PubMed ID: 3866331
[No Abstract] [Full Text] [Related]
5. [Clinical effects of metharmon F for postmenopausal women with climacteric symptoms: its relationship with serum level of hormones].
Yoshimoto S; Fujita T
Horumon To Rinsho; 1983 Aug; 31(8):815-22. PubMed ID: 6414748
[No Abstract] [Full Text] [Related]
6. [The effect of estrogen and, sex-steroids and thyroid hormone preparation on bone mineral density in senile osteoporosis--a comparative study of the effect of 1 alpha-hydroxycholecalciferol (1 alpha-OHD3) on senile osteoporosis].
Shiraki M; Orimo H
Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):84-95. PubMed ID: 1645679
[TBL] [Abstract][Full Text] [Related]
7. Reagents inducing epidermal proliferation also induce pigmentation: induction of keratinocyte proliferation as a novel strategy for the treatment of vitiligo.
Wu CS; Komine M; Fujimoto S; Ohmatsu H; Kikuchi K; Tada Y; Yu HS; Ohtsuki M; Tamaki K
J Dermatol Sci; 2013 Oct; 72(1):66-8. PubMed ID: 23876305
[No Abstract] [Full Text] [Related]
8. Differences in the melanosome distribution within the epidermal melanin units and its association with the impairing background of leukoderma in vitiligo and halo nevi: a retrospective study.
Xiong XX; Ding GZ; Zhao WE; Li X; Ling YT; Sun L; Gong QL; Lu Y
Arch Dermatol Res; 2017 Jul; 309(5):323-333. PubMed ID: 28314912
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic update on vitiligo.
Sarnoff DS
J Drugs Dermatol; 2015 Feb; 14(2):109-11. PubMed ID: 25689803
[No Abstract] [Full Text] [Related]
10. Giant melanin granules in vitiliginous achromia with malignant melanoma.
Ortonne JP; Perrot H
Acta Derm Venereol; 1978; 58(6):475-80. PubMed ID: 83067
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of piperine and synthetic analogues as potential treatments for vitiligo using a sparsely pigmented mouse model.
Faas L; Venkatasamy R; Hider RC; Young AR; Soumyanath A
Br J Dermatol; 2008 May; 158(5):941-50. PubMed ID: 18284389
[TBL] [Abstract][Full Text] [Related]
12. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
Lan CC; Chen GS; Chiou MH; Wu CS; Chang CH; Yu HS
Br J Dermatol; 2005 Sep; 153(3):498-505. PubMed ID: 16120133
[TBL] [Abstract][Full Text] [Related]
13. Development of melanocye-keratinocyte co-culture model for controls and vitiligo to assess regulators of pigmentation and melanocytes.
Kumar R; Parsad D; Kanwar A; Kaul D
Indian J Dermatol Venereol Leprol; 2012; 78(5):599-604. PubMed ID: 22960816
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of an antioxidant and mitochondria-stimulating cream formula on the skin of patients with stable common vitiligo].
Rojas-Urdaneta JE; Poleo-Romero AG
Invest Clin; 2007 Mar; 48(1):21-31. PubMed ID: 17432541
[TBL] [Abstract][Full Text] [Related]
15. Response of localized, resistant, tingling vitiligo to pregabalin: A case report.
Madura C; Harsha S; Kusuma MR; Chandrashekar BS
Dermatol Ther; 2018 Nov; 31(6):e12702. PubMed ID: 30456812
[TBL] [Abstract][Full Text] [Related]
16. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.
Hariharan V; Klarquist J; Reust MJ; Koshoffer A; McKee MD; Boissy RE; Le Poole IC
J Invest Dermatol; 2010 Jan; 130(1):211-20. PubMed ID: 19657355
[TBL] [Abstract][Full Text] [Related]
17. RALGA (Diacneal) decreases melanin content in a human skin model.
Boisnic S; Branchet-Gumila MC; Nocera T; Verrière F
Dermatology; 2005; 210 Suppl 1():35-8. PubMed ID: 15724106
[TBL] [Abstract][Full Text] [Related]
18. Vitiligo: new and emerging treatments.
Lotti T; Gori A; Zanieri F; Colucci R; Moretti S
Dermatol Ther; 2008; 21(2):110-7. PubMed ID: 18394085
[TBL] [Abstract][Full Text] [Related]
19. Eumelanin and phaeomelanin contents of depigmented and repigmented skin in vitiligo patients.
Parsad D; Wakamatsu K; Kanwar AJ; Kumar B; Ito S
Br J Dermatol; 2003 Sep; 149(3):624-6. PubMed ID: 14510999
[TBL] [Abstract][Full Text] [Related]
20. Repigmentation in vitiligo universalis: role of melanocyte density, disease duration, and melanocytic reservoir.
Dogra S; Kumar B
Dermatol Online J; 2005 Dec; 11(3):30. PubMed ID: 16409926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
